Navigation Links
PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
Date:11/6/2008

CINCINNATI, Nov. 6 /PRNewswire/ -- PDS Biotechnology Corporation today announced that the company has been selected as a collaborator of the US National Cancer Institute's Nanotechnology Characterization Lab (NCL) to complete preclinical development of Versamune(TM)-HPV prior to filing of the Investigational New Drug Application. The NCL will perform selected physical, chemical and biological studies on behalf of the company at its facilities at the National Cancer Institute (NCI) in Frederick, Maryland. Dr. Frank Bedu-Addo, President of the Corporation stated that, "PDS Biotechnology Corporation's partnership with the NCL provides significant value to the company. The invaluable expertise of the NCL's scientists will provide the company with additional expert resources and technologies, and will facilitate rapid development of the product."

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology Corporation was awarded in August 2008, a phase I SBIR grant by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-Melanoma to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology Corporation's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen- presenting cells of the immune system and simultaneously acts a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

PDS Biotechnology Corporation (http://www.pdsbiotech.com) is a Cincinnati, Ohio-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

The NCL is a formal collaboration between the US National Cancer Institute, the US Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST) to rapidly advance promising cancer nanotechnology drugs through regulatory submissions with the FDA.


'/>"/>
SOURCE PDS Biotechnology Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
2. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
3. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
4. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
7. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... May 18, 2017  Two Bayer U.S. Pharmaceutical leaders ... during its recent 28 th Woman of ... event showcases HBA,s longstanding mission of furthering the advancement ... Cindy Powell-Steffen , senior director of ... division, and Libby Howe , a regional business ...
(Date:5/12/2017)... 12, 2017  The China and Canada ... consumes less water, energy and detergent, and features a powerful disinfection ... a shoebox-sized washing machine that washes and sanitizes women,s panties or ... ... compact, and does not require an external water inlet. ...
(Date:5/10/2017)... WASHINGTON , May 10, 2017  The ... doctors or employees of sleep therapy clinics to ... a sleep therapy clinic is involved in a ... as interested in hearing from an employee of ... involved in a kickback scheme to provide medical practice ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... 2017 , ... Starting in May, patients at The Bay Clinic of ... diagnostic test. , Nerve-Express, originally designed for the Navy in the 1980s, measures the ... patient’s autonomic nervous system (ANS). The ANS controls all the critical unconscious functions ...
(Date:5/28/2017)... Winter Haven, FL (PRWEB) , ... May 28, ... ... Physician Partners of America (PPOA), is proud to announce that Sheldon K. Cho, ... on comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques ...
(Date:5/27/2017)... ... May 27, 2017 , ... Hate visiting the dentist? You should go twice per year ... care of your teeth at home. Here are some dental tips to help out: , ... small toothbrush in your work desk or a locker at school for a quick brushing ...
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... Most us ... concern, but a new study from the Osteoarthritis Initiative shows that certain ... knee osteoarthritis. Knowing this in advance may give doctors the opportunity to treat patients ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... executives in the life sciences, offering exclusive access to key decision makers who ...
Breaking Medicine News(10 mins):